Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 10/20 | 0.44 |
| ▸ | PRKCI | P41743 | 1/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | CDK8 | P49336 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | GPR68 | Q15743 | 1/20 | 0.36 |
| ▸ | ATR | Q13535 | 1/20 | 0.35 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2547967 | 1.00 | FYN (0.44) | FYNPRKCICHRNB4CHRNA3CHRNA7 | |
| SCHEMBL2547969 | 1.00 | FYN (0.44) | FYNPRKCICHRNB4CHRNA3CHRNA7 | |
| SCHEMBL3084233 | 0.79 | MAP4K4 (0.44) | FYNLRRK2CDK8KDM4EMEN1 | |
| SCHEMBL1301463 | 0.76 | CDK8 (0.46) | CDK8ALDH1A1 | |
| SCHEMBL1301460 | 0.76 | CDK8 (0.46) | CDK8ALDH1A1 | |
| SCHEMBL1581550 | 0.75 | PRKCI (0.50) | FYNPRKCICHRNB4CHRNA3CHRNA7 | |
| SCHEMBL3650445 | 0.74 | PRKCI (0.51) | FYNPRKCICHRNB4CHRNA3CHRNA7 | |
| SCHEMBL3650131 | 0.72 | PRKCI (0.50) | FYNPRKCICHRNB4CHRNA3CHRNA7 | |
| SCHEMBL13285567 | 0.72 | PRKCI (0.50) | FYNPRKCICHRNB4CHRNA3CHRNA7 | |
| SCHEMBL31500185 | 0.72 | PRKCI (0.50) | FYNPRKCICHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2754660-B1 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2016-11-02 | — | — | EP | disclosed |
| US-9284300-B2 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2016-03-15 | — | — | US | disclosed |
| US-20150011534-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-01-08 | — | — | US | disclosed |
| US-20150011534-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-01-08 | — | — | US | disclosed |
| US-8927540-B2 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2015-01-06 | — | — | US | disclosed |
| US-8927540-B2 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2015-01-06 | — | — | US | disclosed |
| US-8921357-B2 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2014-12-30 | — | — | US | disclosed |
| US-8921357-B2 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2014-12-30 | — | — | US | disclosed |
| EP-2164843-B1 | PYRIDAZINONE DERIVATES | MERCK PATENT GMBH (DE) | 2014-10-29 | — | — | EP | disclosed |
| US-8859547-B2 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2014-10-14 | — | — | US | disclosed |
| US-20100280030-A1 | 2-OXO-3-BENZYLBENZOXAZOL-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS MET KINASE INHIBITORS FOR THE TREATMENT OF TUMOURS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-11-04 | — | — | US | disclosed |
| US-20100280030-A1 | 2-OXO-3-BENZYLBENZOXAZOL-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS MET KINASE INHIBITORS FOR THE TREATMENT OF TUMOURS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-11-04 | — | — | US | disclosed |
| US-20100273796-A1 | 2-BENZYLPYRIDAZINONE DERIVATIVES AS MET KINASE INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-10-28 | — | — | US | disclosed |
| US-20100273796-A1 | 2-BENZYLPYRIDAZINONE DERIVATIVES AS MET KINASE INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-10-28 | — | — | US | disclosed |
| US-20100234354-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20100234354-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-16 | — | — | US | disclosed |
| WO-2009083076-A1 | 2-BENZYLPYRIDAZINONE DERIVATIVES AS MET KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009030333-A1 | THIADIAZINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009006959-A1 | PYRIDAZINONE DERIVATES | MERCK PATENT GMBH (DE) | 2009-01-15 | — | — | WO | disclosed |
| WO-2008148449-A1 | 2-OXO-3-BENZYL-BENZOXAZOL-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS MET KINASE INHIBITORS FOR THE TREATMENT OF TUMORS | MERCK PATENT GMBH (DE) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273796-A1 | 2-BENZYLPYRIDAZINONE DERIVATIVES AS MET KINASE INHIBITORS | ERBB2, RET, MET | FYN 355/4885PRKCI 154/4885CHRNB4 4639/4885 |
| US-20100280030-A1 | 2-OXO-3-BENZYLBENZOXAZOL-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS MET KINASE INHIBITORS FOR THE TREATMENT OF TUMOURS | ERBB2, RET, MET | FYN 469/4885PRKCI 225/4885CHRNB4 4768/4885 |
| US-20150011534-A1 | PYRIDAZINONE DERIVATIVES | MET, RET, ERBB2 | FYN 510/4885PRKCI 883/4885CHRNB4 4375/4885 |
| US-20100234354-A1 | PYRIDAZINONE DERIVATIVES | MET, RET, ERBB2 | FYN 488/4885PRKCI 987/4885CHRNB4 4208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.